The global Migrane Drugs market is expected to reach USD 3.96 billion by 2023 from USD 1.95 million in 2018, growing at a CAGR of 15.2%. Increasing awareness about novel therapies, launch of Calcitonin Gene-related Peptide (CGRP), increasing incidence of migraines and launch of new drugs are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new drugs, thus propelling the market growth.

Note: *Details on Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.* 10 to 15 Market Leaders Will Be Profiled* Segmentation May Change During the Planned Research Work

The global Migrane Drugs market is expected to reach USD 3.96 billion by 2023 from USD 1.95 million in 2018, growing at a CAGR of 15.2%. Increasing awareness about novel therapies, launch of Calcitonin Gene-related Peptide (CGRP), increasing incidence of migraines and launch of new drugs are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new drugs, thus propelling the market growth.

North America dominates the migraine drugs market with the North America accounted major market share in 2017. Established healthcare infrastructure; and increasing demand for preventive migraine treatment options are some of the major driving factors driving the growth of this market in North America. The Asian migraine drugs market is poised to grow at the highest CAGR during the forecast period owing to improving healthcare infrastructure and rising awareness about novel treatments among people in the region. The rising focus of prominent players on the Asian migraine drugs market is another factor driving its growth. Furthermore, emerging countries such as India and China provides immense growth opportunities to the migraine drug manufacturers.